Granted that this is a first-time mention of Moleculin Biotech Inc (NASDAQ:MBRX) here on Street Register, we like to help our readers out by giving a brief explanation of what the company is, before delving into any recent news.
Moleculin Biotchech is a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center.
It has been a busy week Moleculin Biotech Inc (NASDAQ:MBRX). First the company announced it will host a conference call on Thursday, June 29, 2017 at 4:30 PM ET to discuss the recent new discovery of a metabolic inhibitor with the potential to treat pancreatic cancer as well as to provide a business update.
“We’ve received a lot of attention from the scientific community for our glucose decoy technology as a potential means to starve tumors to death by exploiting their hyper-dependence on glycolysis for energy production,” commented Walter Klemp, Chairman and CEO of Moleculin, “and now we have identified possible new properties of our compound WP1234, a modification to WP1122. In pre-clinical testing, WP1234 has shown improved drug characteristics when compared with WP1122 and a 20 to 50-fold greater ability to kill pancreatic cancer cell lines when compared with traditional inhibitors of glycolysis. We know that pancreatic cancer thrives even in a reduced oxygen environment, which indicates it may be highly dependent on glycolysis to survive. This discovery now makes WP1234 a promising drug candidate to be studied for the treatment of pancreatic cancer.” (Source: Marketwired)
Next it was revealed that MBRX entered into an agreement with a physician at the Mayo Clinic to enable additional research on Moleculin’s WP1066 molecule for the possible treatment of a rare form of pediatric brain tumor.
Mayo Clinic physician-scientists have requested and Moleculin has agreed to supply them with WP1066 for preclinical testing for the potential treatment of pediatric Diffuse Intrinsic Pontine Gliomas (DIPG), a rare and very aggressive form of brain tumor. Mayo Clinic studies have suggested that DIPG may be particularly sensitive to the inhibition of the activated form of a cell-signaling protein called STAT3, a primary target of WP1066, and their preliminary studies have demonstrated significant anti-tumor activity of WP1066 in DIPG in vitro and in vivo tumor models.
“Independent research now suggests that WP1066 is capable of tumor suppression in xenografts of human brain tumors transplanted into mice,” commented Walter Klemp, Chairman and CEO of Moleculin. “So, we are eager to move WP1066 into the clinic as quickly as possible.”
Mr. Klemp added: “we are proud to have an institution as renown as Mayo Clinic focus on WP1066 as a potential treatment for DIPG. This, along with the physician efforts at MD Anderson to secure an IND to study WP1066 for the treatment of adult brain tumors, continues to validate the potential importance of WP1066 in the treatment of difficult tumors.” (Source: Marketwired)
With multiple projects in the pipeline attacking multiple types of cancer, one of the leading killers of people around the world, it really pushes MBRX to the forefront of speculative pharma plays. We want to continually track this stock moving forward, especially considering the impressive uptrend it is currently building upon. Stay locked to Street Register for updates, and we’ll deliver important developments on MBRX as they unfold. In the meantime, if you’ve yet to sign up for our 100% free newsletter, do so now! Just enter your active email address into the box below and submit!
Disclosure: No one at Street Register has been compensated in any way for the publishing of this article, nor do we hold any position in MBRX stock, short or long.